Company Overview - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [3] - The company is working on its investigational drug candidate, certepetide, which utilizes a novel uptake pathway to enhance the targeting and penetration of anti-cancer drugs in solid tumors [3] Upcoming Event - David J. Mazzo, PhD, President and CEO of Lisata, will present a corporate overview at the Sequire Investor Summit scheduled for January 21-23, 2025, in San Juan, Puerto Rico [1][2] - The presentation is set for January 22 at 10:00 a.m. Atlantic Standard Time [2] Financial and Operational Outlook - Lisata has established significant commercial and R&D partnerships based on its CendR Platform® technology [3] - The company anticipates announcing multiple milestones over the next 1.5 years and projects that its capital will support operations into early 2026, including data milestones from ongoing and planned clinical trials [3]
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit